HomeTrading NewsMeme Stocks, De-SPACS and Biotech Slump in Rough Start to 2022

Meme Stocks, De-SPACS and Biotech Slump in Rough Start to 2022

(Bloomberg) — Meme stocks, blank-check companies and high-flying biotech names that were all the rage at the start of 2021 are now running cold.

Most Read from Bloomberg

One of the World’s Wealthiest Oil Exporters Is Becoming Unlivable

Djokovic Loses Shot at Tennis History as Australia Deports Star

Putin’s Troops Wouldn’t Get Cheers in This Once Pro-Russia City

The Virus Has Changed. Maybe We Should, Too.

DirecTV to Drop One America News in Blow to Conservative Channel

The first two weeks of the year have brought a 17% tumble for a group of stocks that went public via merger with blank-check firms and a 10% correction for the biotechnology industry.

That’s a very different picture from a year ago when investors pushed easy money into the SPAC bubble or high-flying stocks backed by the portfolio of exchange-traded funds in Cathie Wood’s ARK Investment Management.

The frenzy of special-purpose acquisition companies has fizzled over the past 10 months as investors shy away from the vehicle. The De-SPAC Index, a group of 25 stocks that went public by merging with a SPAC, has slumped 17% to start the year, descending into a string of fresh record lows.

Another casualty of the market’s choppy start to 2022 are meme stocks, the group of companies which saw a parabolic rise this time last year. GameStop Corp., the stock that gripped the market, has lost more than one-fifth of its value to start the year and is mired in its longest losing streak since early August.

Retail investor malaise has weighed on the broader meme stock ecosystem with a Bloomberg-tracked basket trading roughly where it was last year before the mania consumed the market.

The group of 37 stocks is down more than 7% this year, which compares with a more than 30% rally the index saw to start 2021.

A beneficiary of the surge in thematic ETFs was Wood’s suite of ARK ETFs. While its flagship ARK Innovation ETF (ARKK) rallied 14% at the start of 2021, outperforming a flat S&P 500, it has been caught in a vicious downward spiral this year. ARKK has fallen 15% to start the year with losses more than tripling the tech-heavy Nasdaq 100 Index.

Weakness is apparent in the biotechnology industry and stands out for trading of the equal-weighted SPDR S&P Biotech ETF (XBI). The ETF, which is tracked by fund specialists to measure the industry’s performance, has slumped 10% this year after its worst year ever. That rocky performance has extended into 2022 with the ETF bouncing off the lowest level since May 2020.

A lack of mergers and acquisitions and the general risk-off environment are among the factors experts blame for the latest leg lower.

Most Read from Bloomberg Businessweek

A $13 Billion Bet That Air Travel Will Soon Take Off

One Thing Covid Can’t Stop: Alcohol Sales

As Fintech Eats Into Profits, Big Banks Fight Back in Washington

For Macron and France, It’s the Economy, Stupide

No, Really, Flying Taxis Are Getting Close to Takeoff

©2022 Bloomberg L.P.

No comments

leave a comment